MediciNova announces new data on MN-166 (ibudilast) in tissue analysis of glioblastoma tumors presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics

MediciNova, Inc.

LA JOLLA, Calif., Feb. 20, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical corporate traded at the NASDAQ International Marketplace (NASDAQ:MNOV) and the JASDAQ Marketplace of the Tokyo Reserve Alternate (code quantity: 4875 ) , introduced as of late that MediciNova Analysis Laborer Justin Lathia, PhD, Clinical Director of the Rose Ella Burkhardt Mind Tumor and Neuro-Oncology Heart on the Cleveland Sanatorium and Lecturer, Section of Molecular Drugs on the Cleveland Sanatorium Lerner Faculty of Drugs, the case Western Book College , Lecturer and Vice Chair of the Section of Cardiovascular and Metabolic Sciences on the Lerner Analysis Institute, Cleveland Sanatorium, offered unutilized information on tumor tissue research and scientific result of a glioblastoma scientific trial (Protocol #MN-166-GBM- 1201; NCT03782415) on the twentieth Annual SBMT (Population for Mind Mapping and Therapeutics) International Congress to be held 16-19 Fe February 2023 in Los Angeles, CA.

This tumor research find out about used to be a collaborative try of MediciNova, Dr. Patrick Wen (Dana Farber Most cancers Institute) and Dr. Lathia (Cleveland Sanatorium Substructure). MN-166-GBM-1201 is an ongoing Segment 1/2 find out about, focused on recurrent and newly identified glioblastoma, being performed on the Dana-Farber Most cancers Institute beneath Most important Investigator: Dr. Wen, Director on the Heart for Neuro-Oncology Dana-Farber Most cancers Institute, Lecturer of Neurology, Harvard Scientific College.

The highlights of the presentation by means of Dr. Lathia are as follows:

• Tumor tissues had been analyzed to resolve doable predictors of medication reaction to mixture medication with MN-166 (ibudilast) and temozolomide (TMZ).

• Pre-treatment tumor tissue used to be bought from the resected tumors on the first surgical treatment or biopsy of analysis contributors (Phase 1) identified with recurrent glioblastoma.

• Immunohistochemistry used to be carried out on resected tumor tissue to evaluate MIF (macrophage migration inhibitory issue), pERK, Ki67, CD3, CD11b and CD74. A masked researcher calculated the ranking for each and every protein in keeping with affected person.

• Learn about contributors had been divided into two teams: non-responders (problem development inside 5 months of receiving MN-166 and TMZ) and responders (incorrect problem development inside 5 months of receiving MN-166 and TMZ).

• Responders had a decrease proportion of CD3+ T cells than non-responders (p

• CD3 voice used to be the most efficient predictor of tumor development over 5 months in sufferers with recurrent glioblastoma handled with MN-166 and TMZ.

dr Lathia commented, “We previously reported that MN-166, as a brain-penetrating MIF-CD74 interaction inhibitor, reduced myeloid suppressor cell (MDSC) formation and reversed their T-cell-suppressing capacity in vitro. Furthermore, in a mouse model study, MN-166 reduced monocyte MDSCs and increased the number and function of CD8+ T cells in the tumor microenvironment. These new findings from clinical tumor tissue analysis can be explained by treatment with MN-166, which resulted in increased CD3+ infiltration into tumor tissue in the patients who started with low CD3+ due to high MDSCs. This needs to be confirmed in a larger cohort.”

Kazuko Matsuda, MD Ph.D, MPH, Eminent Scientific Officer, MediciNova, Inc. commented, “GBM is the most common primary malignant brain tumor and has a poor prognosis. It is a highly immunosuppressive tumor and there are limitations to the extent of a safe immune response in the central nervous system. We are from those of Dr. Lathia was enthusiastic about the results presented. We recently completed study recruitment for the MN-166-GBM-1201 study and look forward to the upcoming data analysis with additional tissue samples.”

About glioblastoma

In step with the American Affiliation of Neurological Surgeons, glioblastoma is an competitive mind tumor this is regularly appalling throughout the first 15 months next analysis. Glioblastoma develops from glial cells (astrocytes and oligodendrocytes), grows abruptly, and regularly spreads to within reach mind tissue. Glioblastoma is classed as Grade IV, the perfect grade, within the International Fitness Group (WHO) mind tumor grading machine. The American Mind Tumor Affiliation experiences that glioblastoma accounts for about 15% of all number one mind tumors and roughly 10,000 circumstances of glioblastoma are identified each and every future in the USA. In spite of many years of advances in neuroimaging, neurosurgery, chemotherapy, and radiation treatment, best tiny enhancements were made and diagnosis has now not stepped forward for people identified with glioblastoma. The median survival is roughly 11-15 months for adults with extra competitive glioblastoma (IDH wild-type) receiving a typical of lend a hand consisting of surgical treatment, temozolomide, and radiation treatment.

By the use of MN-166 (Ibudilast)

MN-166 (Ibudilast) is a tiny molecule compound that inhibits phosphodiesterase sort 4 (PDE4) and inflammatory cytokines, together with macrophage migration inhibitory issue (MIF). It’s in past due scientific construction for the medication of neurodegenerative sicknesses equivalent to ALS (amyotrophic lateral sclerosis), determined MS (a couple of sclerosis) and DCM (degenerative cervical myelopathy); and could also be in construction for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance virtue issues. As well as, MN-166 (ibudilast) has been studied in sufferers vulnerable to growing acute breathing misery syndrome (ARDS).

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical corporate growing a extensive pipeline of booklet tiny molecule remedies for late-stage inflammatory, fibrotic and neurodegenerative sicknesses. According to two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with a couple of mechanisms of motion and robust protection profiles, MediciNova has 11 methods in scientific construction. MediciNova’s manage compound, MN-166 (ibudilast), is recently in Segment 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is able for Segment 3 for determined a couple of sclerosis (MS). MN-166 (ibudilast) could also be being investigated in section 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) has been evaluated in a section 2 find out about in idiopathic pulmonary fibrosis (IPF) and a 2d section 2 find out about in nonalcoholic fatty liver problem (NAFLD) is ongoing. MediciNova has a powerful observe report of securing investigator-sponsored scientific trials funded by means of executive grants.

Statements on this press loose that don’t seem to be historic in nature represent forward-looking statements throughout the that means of the secure harbor provisions of the Personal Securities Litigation Reform Office of 1995. Those forward-looking statements come with, with out limitation, statements in regards to the day efficiency and effectiveness of MN- 166, MN-001, MN-221 and MN-029. Those forward-looking statements is also preceded, adopted, or differently contained by means of the phrases “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “may”, “could”. might”, “will”, “would”, “consider”, “plan” or matching expressions. Those forward-looking statements contain quite a few dangers and uncertainties that would reason fresh effects or occasions to range materially from the ones expressed or implied by means of such forward-looking statements. Components that would reason fresh effects or occasions to range materially from the ones expressed or implied by means of those forward-looking statements come with, amongst others, the danger of acquiring day companions or investment for the advance of MN-166, MN-001 , serve MN-221 and MN-029 and dangers of elevating capital required to investmrent operations and MediciNova’s contribution to scientific construction, dangers and uncertainties related to scientific trials, together with doable prices, anticipated timing and dangers indistinguishable to scientific trials designed to fulfill the necessities of FDA pointers and the feasibility of additional construction taking into consideration those elements, product construction and commercialization dangers, the hesitancy of whether or not scientific trial effects will backup ends up in nearest levels of product construction construction, the danger of delays or failure to procure or conserve regulatory favor, dangers related to reliance on 3rd events to sponsor and investmrent scientific trials, dangers indistinguishable to Intel highbrow detail rights in product applicants and the facility to virtue them secure and implement highbrow detail rights, the danger of failure of the 3rd events on which MediciNova is based to habits its scientific trials and develop its product applicants to accomplish as anticipated, the danger of larger prices and delays because of delays in creation, the registration, crowning glory or research of scientific trials or vital problems indistinguishable to the adequacy of scientific trial design or habits of scientific trials and the timing of expected regulatory submissions, MediciNova mi collaboration t 3rd events, the supply of price range to finish product construction plans and MediciNova’s talent to procure 3rd celebration investment for methods and to lift enough capital when wanted, and the alternative dangers and uncertainties inherent in MediciNova’s filings with the Securities and Alternate Fee, together with its Annual File on Method described are 10-Ok for the future ended December 31, 202 2 and next periodic experiences on Method 10-Q and flow experiences on Method 8-Ok. Undue reliance must now not be put on those forward-looking statements, which discuss best as of the time of this loose. MediciNova disclaims any goal or legal responsibility to revise or replace those forward-looking statements.

INVESTOR CONTACT:
Geoff O’Brien
Vice President
MediciNova, Inc.
[email protected]

Source